Description:

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2016’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Adrenal Cortex Cancer)
- The report reviews pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics and enlists all their major and minor projects
- The report assesses Adrenocortical Carcinoma (Adrenal Cortex Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Adrenocortical Carcinoma (Adrenal Cortex Cancer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Adrenal Cortex Cancer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents:

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6
Therapeutics Development 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis 8

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics under Development by Companies 9

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics under Investigation by Universities/Institutes 10

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Products under Development by Companies 13

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Products under Investigation by Universities/Institutes 14

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Companies Involved in Therapeutics Development 15

ArQule, Inc. 15

EnGeneIC Ltd 16

Merck KGaA 17

Orphagen Pharmaceuticals, Inc. 18

Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

ARQ-087 - Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

ATR-101 - Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

avelumab - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
TargomiRs - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Recent Pipeline Updates 36
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 42
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 43
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 44
Featured News & Press Releases 44
Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016 44
Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015 44
Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers 45
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2016 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by ArQule, Inc., H1 2016 15
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by EnGeneIC Ltd, H1 2016 16
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Merck KGaA, H1 2016 17
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Therapeutics – Recent Pipeline Updates, H1 2016 36
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Dormant Projects, H1 2016 42
Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Discontinued Products, H1 2016 43

List of Figures
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H1 2016 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) – Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Molecule Types, H1 2016 26

Companies Mentioned:
ArQule, Inc.
EnGeneIC Ltd
Merck KGaA
Orphagen Pharmaceuticals, Inc.

License Types:
Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL: https://www.marketresearchreports.com/global-markets-direct/adrenocortical-carcinoma-adr-
nal-cortex-cancer-pipeline-review-h1-2016

Links